Canbex Therapeutics Secures TSB Biocatalyst Grant
News Sep 06, 2013
Canbex Therapeutics Ltd has announced that it has secured a grant of £1.25M to further support the development of VSN16R.
Alongside our recent financing round the grant secures the early development of this novel treatment for spasticity in multiple sclerosis.
“The goal of the Canbex programme is to set a new standard in the treatment of spasticity through improved tolerability,” said Jesse Schulman, CEO of Canbex. “Spasticity is among the most serious and debilitating symptoms of MS. VSN16R, our lead investigational candidate, has the potential to make a difference to people with MS.”
Keith Powell , chairman of Canbex said “ We are very grateful for the support of the Biocatalyst fund from the TSB. The grant enables us to deliver a very high quality of program in the first human trials, starting next month, and we anticipate will deliver a phase 2 ready project within a year. The grant will also enable supporting studies in the laboratories of Prof David Baker at Queen Mary, University of London and Prof David Selwood, the inventor of VSN16R at UCL.”
Canbex is a spin-out of University College London (UCL) and was founded by a leading scientific and clinical team including Professor David Baker and Professor David Selwood, who were later joined by Professor Gavin Giovannoni, a practicing MS clinician who is a global leader in MS drug development and clinical research.
The company received a Translation Award from the Wellcome Trust in 2011 to support preclinical development of VSN16R.